Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients-Reference-Cited by-同舟云学术

Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients

Published:2010-10-11 Issue:5 Volume:52 Page:1590-1599
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

de Bruijne Joep,Bergmann Jilling F.,Reesink Henk W.,Weegink Christine J.,Molenkamp Richard,Schinkel Janke,Tong Xiao,Li Jing,Treitel Michelle A.,Hughes Eric A.,van Lier Jan Jaap,van Vliet Andre A.,Janssen Harry L. A.,de Knegt Robert J.

Publisher

Wiley

Subject

Hepatology

Reference27 articles.

1. Treating hepatitis C infection in liver transplant recipients;Terrault;Liver Transpl,2006

2. Hepatitis C virus infection;Lauer;N Engl J Med,2001

3. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies;Micallef;J Viral Hepat,2006

4. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial;Manns;Lancet,2001

5. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection;McHutchison;N Engl J Med,2009

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis of Gem-Dimethyl Bicyclic [3.1.0] Proline as an Antiviral Drug Intermediate;Mini-Reviews in Organic Chemistry;2024-04-29

2. Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016–2020): A Recapitulation of Chirality;Pharmaceuticals;2023-02-22

3. Comparative evaluation of the effectiveness of narlaprevir in the composition of interferon and interferon-free treatment regimens for patients with chronic hepatitis C;Terapevticheskii arkhiv;2022-10-12

4. Curing Hepatitis C with Direct‐Acting Antiviral Therapy;New Drug Development for Known and Emerging Viruses;2021-12-03

5. A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease;PLOS ONE;2021-02-01